Temporal trends and projections of hypertension with hyperlipidemia-related mortality among US adults, 2000–2035: Insights from CDC WONDER database

Q: What are the key findings of this study?

Hypertension and hyperlipidemia-related age-adjusted mortality rates in US adults rose from 5.86 to 37.28 per 100,000 between 2000 and 2023 (AAPC 8.34; p<0.001).

Q: What is the clinical evidence from this study?

Study design: Observational. Population: Hypertension with hyperlipidemia (n=1156335). Intervention: Hypertension and hyperlipidemia. Primary outcome: Age-adjusted mortality rates (AAMRs) per 100,000 population and average annual percent change (AAPC) (AAPC 8.34, p=<0.001).

Q: What does this research mean for the field?

Hypertension- and hyperlipidemia-related age-adjusted mortality rates among US adults increased substantially from 5.86 to 37.28 per 100,000 between 2000 and 2023, accompanied by marked demographic and geographic disparities. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Q: What question did this study set out to answer?

To evaluate temporal trends and demographic disparities in mortality associated with hypertension and hyperlipidemia among United States adults from 2000 to 2035.

Saifullah Khan; Muhammad Vazaym; Muhammad Jawad; Nisha Khalid; Pari Kotak; Muhammad Hassan; Muhammad Hussain; Muskan Devi; Muhammad Mubashir; Asma Naz; Ilsa Fatima

doi:10.1016/j.jnma.2026.101127

October 31, 2026Journal of the National Medical Association

Temporal trends and projections of hypertension with hyperlipidemia-related mortality among US adults, 2000–2035: Insights from CDC WONDER database

View at Publisher

Ask AI

Bookmark

Share

Key result

Hypertension- and hyperlipidemia-related mortality in US adults increased ~6-fold from 2000 to 2023.

AAPC 8.34
P<0.001
n=1,156,335

Journal of the National Medical Association published a graphical abstract

Its licence doesn't allow us to show a copy here.

View on journal site ↗

Why the study?

Hypertension and hyperlipidemia frequently coexist, synergistically increase cardiovascular risk, and remain inadequately controlled in many individuals despite treatment advances. Temporal trends and projections of mortality associated with these conditions in the United States from 2000 to 2035 needed evaluation.

Key Points

To evaluate temporal trends and demographic disparities in mortality associated with hypertension and hyperlipidemia among United States adults from 2000 to 2035.
Retrospective population-based analysis of 1,156,335 decedents aged ≥25 years from the CDC WONDER Multiple Cause of Death database (2000–2023) with hypertension (ICD-10: I10-I15) or hyperlipidemia (ICD-10: E78) on death certificates.
Calculated age-adjusted mortality rates (AAMRs) per 100,000 using the 2000 US standard population, using Joinpoint regression to determine annual percent change (APC) and average annual percent change (AAPC) across demographic and geographic strata.
Overall AAMRs rose from 5.86 (95% CI: 5.74–5.97) in 2000 to 37.28 (95% CI: 37.05–37.51) per 100,000 in 2023, reflecting a significant overall increase (AAPC: 8.34; p < 0.001).
Mortality was higher in males than females (AAPC: 8.50 vs. 7.93; both p < 0.001), with the largest burden among adults aged ≥65 years (AAPC: 8.82; p < 0.001) and the highest mean AAMR among non-Hispanic Black individuals (AAPC: 8.21; p < 0.001).
Geographic analyses demonstrated the fastest increases in mortality rates in the South (AAPC: 8.84; p < 0.001) and non-metropolitan regions (AAPC: 9.76; p < 0.001).

Study Design

Type

Observational (n=1,156,335)

Structured PICO

P

Population

1,156,335 deaths among US adults aged ≥25 years with hypertension and hyperlipidemia recorded on death certificates from 2000 to 2023.

E

Exposure

Coexisting hypertension and hyperlipidemia exposure assessed across temporal trends from 2000 to 2023 (with projections to 2035)

O

Outcome

Age-adjusted mortality rates (AAMRs) per 100,000 population and average annual percent change (AAPC) from 2000 to 2023hard clinical

Main Result

Effect estimate: AAPC 8.34

Absolute Event Rate: 37.28% vs 5.86%

p-value: p=<0.001

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Hypertension- and hyperlipidemia-related mortality in the US rose substantially between 2000 and 2023 with marked demographic and regional disparities, underscoring the need for improved cardiometabolic prevention and equitable care.

Abstract

BACKGROUND: Hypertension and hyperlipidemia are highly prevalent cardiometabolic disorders and major contributors to cardiovascular morbidity and mortality. These conditions frequently coexist and synergistically increase cardiovascular risk through mechanisms including endothelial dysfunction, vascular inflammation, and atherosclerosis. Despite advances in treatment, many individuals remain inadequately controlled. This study evaluated temporal trends in mortality associated with hypertension and hyperlipidemia in the United States from 2000 to 2035. METHODS: A retrospective population-based analysis was conducted using the CDC WONDER Multiple Cause of Death database. Adults aged ≥25 years with hypertension (ICD-10: I10-I15) or hyperlipidemia (ICD-10: E78) listed on death certificates were included. Age-adjusted mortality rates (AAMRs) per 100,000 population were calculated using the 2000 U.S. standard population. Temporal trends were assessed using Joinpoint regression to estimate annual percent change (APC) and average annual percent change (AAPC). Analyses were stratified by sex, age, race/ethnicity, region, and urbanization. RESULTS: From 2000 to 2023, 1,156,335 deaths were recorded. AAMRs increased from 5.86 (95% CI: 5.74-5.97) to 37.28 (95% CI: 37.05-37.51), with a significant overall rise (AAPC: 8.34; p < 0.001). Mortality was consistently higher in males than females (AAPC: 8.50 vs. 7.93; both p < 0.001). All racial and ethnic groups showed increasing trends, with the highest mean AAMR among non-Hispanic Black individuals (AAPC: 8.21; p < 0.001). Older adults (≥65 years) had the greatest mortality burden (AAPC: 8.82; p < 0.001). The South (AAPC: 8.84; p<0.001) and non-metropolitan areas (AAPC: 9.76; p < 0.001) demonstrated the fastest-rising mortality rates. CONCLUSION: Hypertension- and hyperlipidemia-related mortality rose substantially with marked disparities, highlighting the need for improved prevention and equitable care.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Khan et al. (2026) conducted an observational in Hypertension with hyperlipidemia (n=1,156,335). Hypertension and hyperlipidemia was evaluated on Age-adjusted mortality rates (AAMRs) per 100,000 population and average annual percent change (AAPC) (AAPC 8.34, p=<0.001). Hypertension and hyperlipidemia-related age-adjusted mortality rates in US adults rose from 5.86 to 37.28 per 100,000 between 2000 and 2023 (AAPC 8.34; p<0.001).

synapsesocial.com/papers/6ae7403e166b62faa6784d6a https://doi.org/10.1016/j.jnma.2026.101127

View at Publisher

Ask AI

Bookmark

Share

Temporal trends and projections of hypertension with hyperlipidemia-related mortality among US adults, 2000–2035: Insights from CDC WONDER database

Journal of the National Medical Association published a graphical abstract

Key Points

Study Design

Structured PICO

Main Result

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Temporal trends and projections of hypertension with hyperlipidemia-related mortality among US adults, 2000–2035: Insights from CDC WONDER database

Journal of the National Medical Association published a graphical abstract

Key Points

Study Design

Structured PICO

Main Result

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading